KalshiVerifica disponibilitàKYC richiestoDati di risoluzione verificatiBen calibratoPunto medio del book selezionato
No · —
Caricamento del book selezionato…
—
Prezzo registrato
No 86.5%
No 86.5%Qualità del mercato
78 / 100
Alta qualitàVolume 24h
925,4 €
Open interest
95,9K USD
Open interest altoBid / Ask
— / —
NoSpread
—
Dati di mercato
Aggiornato 12 minuti fa
17 lug 25, 14:00 UTC1 gen 27, 04:59 UTC
Il grafico e le variazioni mostrano probabilità storiche salvate, non il book selezionato in tempo reale.
Trend
Riga selezionata: punto medio del book. Altre righe: riferimenti salvati, eventualmente normalizzati; le variazioni a 24h usano lo storico salvato.
Condizioni della piattaforma
Fonte: Kalshi
Queste condizioni sono informative; il trading simulato di CoinRithm segue regole proprie.
- Chiusura anticipata:
- Sì
- Tempo di liquidazione:
- 30m (indicativo)
Profondità di mercato · No
Caricamento del book selezionato…
—
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Will the FDA approve any psychedelic substance for medical use before 2028?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill a psychedelic substance get de-scheduled by the US by 2030?
Manifold MarketsWill the FDA approve cytisinicline for smoking cessation?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsRegole
La regola esatta di questo esito non è disponibile.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.
Regole per ogni esito
- No
- La regola esatta di questo esito non è disponibile.
- Yes
- La regola esatta di questo esito non è disponibile.
